Cost-comparison analysis of a multiplatform tumour profiling service to guide advanced cancer treatment

Autor:	Gilbert Spizzo, Andreas Seeber, Robert C. F. Leonard, Guenther Gastl, Uwe Siebert, Klaus Schuster, Andreas Voss
Jazyk:	angličtina
Rok vydání:	2019
Předmět:	medicine.medical_specialty Cost effectiveness 03 medical and health sciences Molecular profiling 0302 clinical medicine Internal medicine medicine health care economics and organizations 030304 developmental biology 0303 health sciences lcsh:R5-920 Health economics Cost comparison business.industry Health Policy Standard treatment Research Health services research CARIS multiplatform Advanced cancer Clinical trial 030220 oncology & carcinogenesis In situ hybridisation Cancer treatment Cost-effectiveness business lcsh:Medicine (General)
Zdroj:	Cost Effectiveness and Resource Allocation, Vol 17, Iss 1, Pp 1-5 (2019) Cost Effectiveness and Resource Allocation : C/E
ISSN:	1478-7547
DOI:	10.1186/s12962-019-0191-6
Popis:	Background Tumor profiling is increasingly used in advanced cancer patients to define treatment options, especially in refractory cases where no standard treatment is available. Caris Molecular Intelligence (CMI) is a multiplatform tumor profiling service that is comprehensive of next-generation sequencing (NGS) of DNA and RNA, immunohistochemistry (IHC) and in situ hybridisation (FISH). The aim of this study is to compare costs of CMI-guided treatment with prior or planned treatment options in correlation with outcome results. Methods Retrospective data from five clinical trials were collected to define the treatment decision prior to the receipt of the CMI report (n = 137 patients). A systematic review of treatment data from 11 clinical studies of CMI (n = 385 patients) allowed a comparison of planned vs actual (n = 137) and prior vs actual (n = 229) treatment costs. Results Treatment plan was changed in 88% of CMI-profiled cases. The actual CMI guided treatment cost per cycle was £995 in 385 treated patients. Planned treatment costs were comparable to actual treatment costs (£979 vs £945; p = 0.7123) and prior treatment costs were not significantly different to profiling-guided treatments (£892 vs £850; p = 0.631). Conclusions Caris Molecular Intelligence guided treatment cost per cycle was in the range of prior or planned treatment cost/cycle. Due to beneficial overall survival the additional cost of performing CMI’s multiplatform testing to the treatment costs seems to be cost-effective.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2132b1d5ef847ff663f3a1f4a8f14a8b http://link.springer.com/article/10.1186/s12962-019-0191-6 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.